Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 16Neoplasm Metastasis 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Endometrial Neoplasms 2Solid Tumors 1PIK3CA-Mutated Cancers 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Metastatic Castration-Resistant Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Fulvestrant 10Alpelisib 7Everolimus 6Cetuximab 6Letrozole 4serabelisib 3ribociclib 3pembrolizumab 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3NVP-BKM120 3Irinotecan 3sapanisertib 2parsaclisib 2olaparib 2binimetinib 2Topotecan 2Gemcitabine 2Carboplatin 2volagidemab 1venetoclax 1tivozanib 1tipifarnib 1tanezumab 1talazoparib 1sotorasib 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × inavolisib × Clear all
NCT07522697 2026-04-13

MITO END-4

National Cancer Institute, Naples

Phase 2 Not yet recruiting
48 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡